A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2006
11/28/2006	US7141409 Hyaluronan synthase gene and uses thereof
11/28/2006	US7141408 live vector vaccine; removal of sole dependence on catalytic balanced lethal maintenance systems; plasmid partition system prevents random segregation; enhanced inheritance and stability; genetic engineering; antibiotic resistance
11/28/2006	US7141363 Purposeful movement of human migratory cells away from an agent source
11/28/2006	US7141245 Using chilodonella vector to infect and feed on mosquitoe larvae; mosquitoe vectors for treatment of hum an disease; biological pest control
11/28/2006	US7141244 Helicobacter pylori proteins useful for vaccines and diagnostics
11/28/2006	US7141243 gM-negative EHV-mutants without heterologous elements
11/28/2006	US7141242 Hepatitis B virus surface antigen mutant and methods of detection thereof
11/28/2006	CA2311395C Flavivirus expression and delivery system
11/28/2006	CA2076345C Transgenic animals, cells and cell lines therefrom, and their use
11/23/2006	WO2006125229A2 Use of tnf inhibitor for treatment of erosive polyarthritis
11/23/2006	WO2006125202A2 Anti- mcp-1 antibodies, compositions, methods and uses
11/23/2006	WO2006125201A2 Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
11/23/2006	WO2006125200A2 Method for reducing sepsis or cardiogenic shock associated with myocardial injury
11/23/2006	WO2006125143A2 Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
11/23/2006	WO2006125140A2 Methods for treating fibrotic conditions
11/23/2006	WO2006125076A2 Methods and compositions for immunizing against chlamydia infection
11/23/2006	WO2006124712A2 A method for improving the immunogenicity of plasmodium antigens
11/23/2006	WO2006124700A2 P53 vaccines for the treatment of cancers
11/23/2006	WO2006124689A2 Combination therapy
11/23/2006	WO2006124661A1 Prognosis and treatment of breast cancer
11/23/2006	WO2006124630A2 Compositions and methods for enhancing the efficacy of vaccines
11/23/2006	WO2006124627A2 Methods of treating conditions involving neuronal degeneration
11/23/2006	WO2006124412A2 Methods for the rapid expansion of antigen specific t-cells
11/23/2006	WO2006124269A2 Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
11/23/2006	WO2006124063A2 Collision alerting and avoidance system
11/23/2006	WO2006123829A1 ANTIBODY DIRECTED AGAINST PAP2a AND USE THEREOF FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
11/23/2006	WO2006123724A1 Novel pharmaceutical using anti-hla antibody
11/23/2006	WO2006123644A1 Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF
11/23/2006	WO2006123230A2 Compositions for antigen-specific induction of immuno-tolerance via oral immunization
11/23/2006	WO2006123122A2 Psk- i and its modulators for the treatment/diagnosis of cancer
11/23/2006	WO2006122986A2 Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections
11/23/2006	WO2006122964A1 Methods for the production of a whole-inactivated west nile virus vaccine
11/23/2006	WO2006122586A1 Pasteurella multocida vaccine
11/23/2006	WO2006122382A2 Composition comprising fractions or sub-fractions of leishmania promastigotes or leishmania amastigotes called fucose mannose ligand (fml) and saponin, composition for preparation of leishmaniasis transmission blocking vaccines in humans and animals comprising fractions or sub-fractions of leishmania promastigotes or leis
11/23/2006	WO2006122380A1 Antitumor agent on the base of bcg vaccine, method for his preparation and its use
11/23/2006	WO2006108130A3 Methods to measure immunosuppressive tacrolimus, sirolimus, and cyclosporin a complexes in a blood sample
11/23/2006	WO2006097642A3 Composition comprising the n-terminal region of leishmania histone h2b, use thereof for inducing an immune response
11/23/2006	WO2006096861A9 METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
11/23/2006	WO2006094828A3 Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor
11/23/2006	WO2006091721A3 Porcine helicobacter infection
11/23/2006	WO2006088833A3 Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
11/23/2006	WO2006074303A3 Delivery vehicles, bioactive substances and viral vaccines
11/23/2006	WO2006067518A3 Vaccines against neisseria meningitidis
11/23/2006	WO2006060051A3 Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis
11/23/2006	WO2006020480A3 Adenoviral vector compositions
11/23/2006	WO2005110473A3 Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
11/23/2006	WO2005089797A3 Support system in the form of protein-based nanoparticles for the cell-specific enrichment of pharmaceutically active substances
11/23/2006	WO2005086967A3 Therapeutic use of rm1 antigen
11/23/2006	WO2005081711A3 Monomethylvaline compounds capable of conjugation to ligands
11/23/2006	WO2005070180A3 Coccidian parasite casein kinase i as a chemotherapeutic target for antiprotozoal agents
11/23/2006	WO2005001052A3 Modulation of apoptosis
11/23/2006	US20060265773 Methods for producing transgenic animals with modified disease resistance
11/23/2006	US20060265763 Dyrks as modifiersof the apc and axin pathways and methods of use
11/23/2006	US20060264619 Plasmodium falciparum AMA-1 protein and uses thereof
11/23/2006	US20060264618 Protease inhibitor conjugates and antibodies useful in immunoassay
11/23/2006	US20060264614 Diagnosis using inexpensive and reliable reagents; stimulate immune response; can be used to determine the susceptibility of a particular individual to a treatment regimen
11/23/2006	US20060264609 Use of heat shock proteins
11/23/2006	US20060264605 Polypeptides having anti-HIV activity and compositions comprising same
11/23/2006	US20060264466 N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N-'-(4-(2-methylpropyloxy)phenylmethyl)carbamide ; antipsychotic and anti-dyskinetic; use as novel therapeutics, sometimes in conjunction with other therapeutics, for Parkinson's Disease, related human neurodegenerative diseases, and psychosis
11/23/2006	US20060264465 N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N-'-(4-(2-methylpropyloxy)phenylmethyl)carbamide ; antipsychotic and anti-dyskinetic; use as novel therapeutics, sometimes in conjunction with other therapeutics, for Parkinson's Disease, related human neurodegenerative diseases, and psychosis
11/23/2006	US20060264391 Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
11/23/2006	US20060264356 Increased or improved bioavailability of the active agents for oral, intracolonic, pulmonary, and other routes of administrations
11/23/2006	US20060263881 Methods of expanding and selecting disease associated T-Cells
11/23/2006	US20060263854 Immunodiagnostic assays using reducing agents
11/23/2006	US20060263852 Asp2
11/23/2006	US20060263846 S. penumoniae antigens
11/23/2006	US20060263820 Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins
11/23/2006	US20060263804 Functional influenza virus-like particles (VLPs)
11/23/2006	US20060263430 instrument for inducing cytokine and method of inducing cytokine
11/23/2006	US20060263391 Process for the preparation of hypoallergenic mosaic antigens
11/23/2006	US20060263390 Modified saccharides, conjugates thereof, and their manufacture
11/23/2006	US20060263389 Methods and compositions to enhance immune responses via recall antigens
11/23/2006	US20060263388 Injectable or oral administration of a drug with an active ingredient of an extract from inflamed cutaneous tissue of rabbits inoculated with vaccinia virus; side effect reduction
11/23/2006	US20060263387 Vaccination of pigs against disease by administering a first recombinant porcine adenovirus vector stably expressing a heterologous nucleotide sequence encoding the antigenic determinant of the disease, preferably Hog Cholera Virus or Pseudorabies virus
11/23/2006	US20060263386 Vaccines
11/23/2006	US20060263383 Prognostic indicator
11/23/2006	US20060263382 Membrane-permeant peptide complexes for treatment of sepsis
11/23/2006	US20060263381 Peptide epitopes common to antigens of the same multigene family
11/23/2006	US20060263380 IL-12 as an adjuvant for Bordetella pertussis vaccines
11/23/2006	US20060263379 Bordetella pertussis antigen consisting lipopolysaccharide, pertusis toxin, filamentous hemagglutinin, pertactin or abosrbed to alum; interleukin-12 ; enhances cell-mediated immunity in a host
11/23/2006	US20060263378 Nucleic acids and proteins from Streptococcus pneumoniae
11/23/2006	US20060263377 Surface protein of Leptospira
11/23/2006	US20060263376 Pharmaceutical composition comprising PIM-activated NKT cells, and use thereof in therapy
11/23/2006	US20060263375 Antibody-serum protein hybrids
11/23/2006	US20060263374 Antibodies to treat cancer
11/23/2006	US20060263373 Utilization of an aminopeptidase inhibitor
11/23/2006	US20060263372 Cancerous disease modifying antibodies
11/23/2006	US20060263371 Prognostic indicator
11/23/2006	US20060263370 Prognostic indicator
11/23/2006	US20060263369 Administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR); inhibiting angiogenesis
11/23/2006	US20060263368 Targeted chimeric molecules for cancer therapy
11/23/2006	US20060263367 Bispecific antibody devoid of Fc region and method of treatment using same
11/23/2006	US20060263366 Neoplasm specific antibodies and uses thereof
11/23/2006	US20060263365 Method of immunomodulation
11/23/2006	US20060263364 Mammalian chemokines; related reagents
11/23/2006	US20060263363 Anti-interferon gamma antibodies and methods of use thereof
11/23/2006	US20060263362 Cancer metastasis inhibitor
11/23/2006	US20060263361 Pan-kir2dl nk -receptor antibodies and their use in diagnostik and therapy
11/23/2006	US20060263360 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
11/23/2006	US20060263359 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4)

1 ... 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 ... 1823